Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis

References

• Ohayon MM, Priest RG, Zulley J, Smirne S, Paiva T. Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology. 2002;58(12):1826–1833. doi:10.1212/WNL.58.12.1826
   PubMed Web of Science ®Google Scholar
• Ohayon MM. Epidemiology of narcolepsy. In: Bassetti C, Billiard M, Mignot E, editors. Narcolepsy and Hypersomnia. New York: Informa Healthcare; 2007:125–132.
   Google Scholar
• Partinen M, Kronholm E. Epidemiology: Principles and Application in Sleep Medicine. Sleep Disorders Med. 2017:485.
   Google Scholar
• Zhang Z, Mayer G, Dauvilliers Y, et al. Exploring the clinical features of narcolepsy type 1 versus narcolepsy type 2 from European Narcolepsy Network database with machine learning. Sci Rep. 2018;8:10628.
   PubMed Web of Science ®Google Scholar
• American Academy of Sleep Medicine. International Classification of Sleep Disorders. 3rd ed. Darien, IL: American Academy of Sleep Medicine; 2014.
   Google Scholar
• Maski K, Steinhart E, Williams D, et al. Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy. J Clin Sleep Med. 2017;13(3):419–425.
   PubMed Web of Science ®Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021;17(9):1881–1893.
   PubMed Web of Science ®Google Scholar
• Bassetti CLA, Kallweit U, Vignatelli L, et al. European guideline and expert statements on the management of narcolepsy in adults and children. Eur J Neurol. 2021;28(9):2815–2830.
   PubMed Web of Science ®Google Scholar
• Clinical Outcome Assessment Compendium; 2019. Available from: https://www.fda.gov/drugs/development-resources/clinical-outcome-assessment-compendium. Accessed April 6, 2023.
   Google Scholar
• Patel S, Kon SSC, Nolan CM, et al. The Epworth Sleepiness Scale: minimum Clinically Important Difference in Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2018;197(7):961–963.
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Schweitzer PK, Steier J, et al. Residual excessive daytime sleepiness in patients treated for obstructive sleep apnea: guidance for assessment, diagnosis, and management. Postgrad Med. 2021;133(7):772–783.
   PubMed Web of Science ®Google Scholar
• Rosenberg R, Baladi M, Bron M. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021;17(4):711–717.
   PubMed Web of Science ®Google Scholar
• Scammell TE. Narcolepsy. N Engl J Med. 2015;373(27):2654–2662.
   PubMed Web of Science ®Google Scholar
• Littner MR, Kushida C, Wise M, et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep. 2005;28(1):113–121.
   PubMed Web of Science ®Google Scholar
• Busner J, Targum SD. The Clinical Global Impressions Scale. Psychiatry. 2007;4(7):28–37.
   PubMedGoogle Scholar
• Thorpy MJ. Recently Approved and Upcoming Treatments for Narcolepsy. CNS Drugs. 2020;34(1):9–27.
   PubMed Web of Science ®Google Scholar
• Pellitteri G, de Biase S, Valente M, Gigli GL. How treatable is narcolepsy with current pharmacotherapy and what does the future hold? Expert Opin Pharmacother. 2021;22(12):1517–1520.
   PubMed Web of Science ®Google Scholar
• EMA. Xyrem. European Medicines Agency. 2018. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem. Accessed August 3, 2022.
   Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895–1945.
   PubMed Web of Science ®Google Scholar
• Gandhi KD, Mansukhani MP, Silber MH, Kolla BP. Excessive Daytime Sleepiness: a Clinical Review. Mayo Clin Proc. 2021;96(5):1288–1301.
   PubMed Web of Science ®Google Scholar
• Franceschini C, Pizza F, Cavalli F, Plazzi G. A practical guide to the pharmacological and behavioral therapy of Narcolepsy. Neurotherapeutics. 2021;18(1):6–19.
   PubMed Web of Science ®Google Scholar
• Bhattarai J, Sumerall S. Current and Future Treatment Options for Narcolepsy: a Review. Sleep Sci. 2017;10(1):19–27.
   PubMedGoogle Scholar
• Thorpy MJ. Modafinil/Armodafinil in the Treatment of Narcolepsy. In: Goswami M, Thorpy MJ, Pandi-Perumal SR, editors. Narcolepsy: A Clinical Guide. Springer International Publishing; 2016:331–339.
   Google Scholar
• Black J, Swick T, Bogan R, et al. Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy. Sleep Med. 2016;24:57–62.
   PubMed Web of Science ®Google Scholar
• Dauvilliers Y, Bassetti C, Lammers GJ, et al. Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol. 2013;12(11):1068–1075.
   PubMed Web of Science ®Google Scholar
• Lehert P, Falissard B. Multiple treatment comparison in narcolepsy: a network meta-analysis. Sleep. 2018;41:12.
   Web of Science ®Google Scholar
• Lehert P, Szoeke C. Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach. Drugs Context. 2020;9:245.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–784.
   PubMed Web of Science ®Google Scholar
• Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
   PubMed Web of Science ®Google Scholar
• Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13:35.
   PubMed Web of Science ®Google Scholar
• Rücker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. Stat Med. 2014;33(25):4353–4369.
   PubMed Web of Science ®Google Scholar
• Curtin F, Elbourne D, Altman DG. Meta-analysis combining parallel and cross-over clinical trials. III: the issue of carry-over. Stat Med. 2002;21(15):2161–2173.
   PubMed Web of Science ®Google Scholar
• Rücker G. Network meta-analysis, electrical networks and graph theory. Res Synth Methods. 2012;3(4):312–324.
   PubMed Web of Science ®Google Scholar
• Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• Malhotra A, Shapiro C, Pepin JL, et al. Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep. 2020;43(2):zsz220.
   PubMed Web of Science ®Google Scholar
• Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep. 2006;29(9):1189–1194.
   PubMed Web of Science ®Google Scholar
• Thorpy MJ, Shapiro C, Mayer G, et al. A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Ann Neurol. 2019;85(3):359–370.
   PubMed Web of Science ®Google Scholar
• Kushida CA, Shapiro CM, Roth T, et al. Once-nightly sodium oxybate (FT218) demonstrated improvement of symptoms in a Phase 3 randomized clinical trial in patients with narcolepsy. Sleep. 2022;45(6):zsab200.
   PubMed Web of Science ®Google Scholar
• Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep. 1994;17(8 Suppl):S107–112.
   PubMed Web of Science ®Google Scholar
• Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology. 1997;49(2):444–451.
   PubMed Web of Science ®Google Scholar
• Saletu M, Anderer P, Saletu-Zyhlarz GM, Mandl M, Saletu B, Zeitlhofer J. Modafinil improves information processing speed and increases energetic resources for orientation of attention in narcoleptics: double-blind, placebo-controlled ERP studies with low-resolution brain electromagnetic tomography (LORETA). Sleep Med. 2009;10(8):850–858.
   PubMed Web of Science ®Google Scholar
• Moldofsky H. A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsy. Sleep Med. 2000;1(2):109–116.
   PubMed Web of Science ®Google Scholar
• Kollb-Sielecka M, Demolis P, Emmerich J, Markey G, Salmonson T, Haas M. The European Medicines Agency review of pitolisant for treatment of narcolepsy: summary of the scientific assessment by the Committee for Medicinal Products for Human Use. Sleep Med. 2017;33:125–129.
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology. 2000;54(5):1166–1175.
   PubMed Web of Science ®Google Scholar
• US Xyrem® Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42–49.
   PubMed Web of Science ®Google Scholar
• US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol. 1998;43(1):88–97.
   PubMed Web of Science ®Google Scholar
• Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep. 2006;29(7):939–946.
   PubMed Web of Science ®Google Scholar
• Harsh JR, Hayduk R, Rosenberg R, et al. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin. 2006;22(4):761–774.
   PubMed Web of Science ®Google Scholar
• US Xyrem® Multicenter Study Group. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002;25(1):42–49.
   PubMed Web of Science ®Google Scholar
• Xyrem International Study Group. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med. 2005;1(4):391–397.
   PubMed Web of Science ®Google Scholar
• Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200–207.
   PubMed Web of Science ®Google Scholar
• Bogan RK, Feldman N, Emsellem HA, et al. Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy. Sleep Med. 2015;16(9):1102–1108.
   PubMed Web of Science ®Google Scholar
• Ruoff C, Swick TJ, Doekel R, et al. Effect of Oral JZP-110 (ADX-N05) on Wakefulness and Sleepiness in Adults with Narcolepsy: a Phase 2b Study. Sleep. 2016;39(7):1379–1387.
   PubMed Web of Science ®Google Scholar
• Bogan RK, Thorpy MJ, Dauvilliers Y, et al. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy. Sleep. 2021;44(3):zsaa206.
   PubMed Web of Science ®Google Scholar
• Yoss RE, Daly D. Treatment of narcolepsy with Ritalin. Neurology. 1959;9(3):171.
   PubMed Web of Science ®Google Scholar
• Rasmussen N. America’s first amphetamine epidemic 1929–1971: a quantitative and qualitative retrospective with implications for the present. Am J of Public Health. 2008;98(6):974–985.
   PubMed Web of Science ®Google Scholar
• Morton WA, Stockton GG. Methylphenidate abuse and psychiatric side effects. Prim Care Companion J Clin Psychiatry. 2000;2(5):159–164.
   PubMedGoogle Scholar
• Wang J, Yang S, Li X, et al. Efficacy and safety of solriamfetol for excessive sleepiness in narcolepsy and obstructive sleep apnea: findings from randomized controlled trials. Sleep Med. 2021;79:40–47.
   PubMed Web of Science ®Google Scholar
• Alshaikh MK, Tricco AC, Tashkandi M, Mamdani M, Straus SE, BaHammam AS. Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis. J Clin Sleep Med. 2012;8(4):451–458.
   PubMed Web of Science ®Google Scholar
• Chapman JL, Vakulin A, Hedner J, Yee BJ, Marshall NS. Modafinil/armodafinil in obstructive sleep apnoea: a systematic review and meta-analysis. Eur Respir J. 2016;47(5):1420–1428.
   PubMed Web of Science ®Google Scholar
• Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev. 2012;16(5):431–443.
   PubMed Web of Science ®Google Scholar
• Medarov BI, Victorson DE, Judson MA. Patient-reported outcome measures for sleep disorders and related problems: clinical and research applications. CHEST. 2013;143(6):1809–1818.
   PubMed Web of Science ®Google Scholar
• CDER Patient-Focused Drug Development. Available from: https://www.fda.gov/drugs/development-approval-process-drugs/cder-patient-focused-drug-development. Accessed April 6, 2023.
   Google Scholar
• Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895–1945.
   PubMed Web of Science ®Google Scholar
• Mignot EJM. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739–752.
   PubMed Web of Science ®Google Scholar
• Schwartz JRL, Feldman NT, Bogan RK, Nelson MT, Hughes RJ. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol. 2003;26(5):252–257.
   PubMed Web of Science ®Google Scholar
• Subedi R, Singh R, Thakur RK, Jha KCB. D, Ray BK. Efficacy and safety of solriamfetol for excessive daytime sleepiness in narcolepsy and obstructive sleep apnea: a systematic review and meta-analysis of clinical trials. Sleep Med. 2020;75:510–521.
   PubMed Web of Science ®Google Scholar
• Kim D. Practical Use and Risk of Modafinil, a Novel Waking Drug. Environ Health Toxicol. 2012;27:e2012007.
   PubMedGoogle Scholar
• Golicki D, Bala MM, Niewada M, Wierzbicka A. Modafinil for narcolepsy: systematic review and meta-analysis. Med Sci Monit. 2010;16(8):RA177–186.
   PubMed Web of Science ®Google Scholar
• Baladi MG, Forster MJ, Gatch MB, et al. Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018;366(2):367–376.
   PubMed Web of Science ®Google Scholar
• Nishino S. Clinical and neurobiological aspects of narcolepsy. Sleep Med. 2007;8(4):373–399.
   PubMed Web of Science ®Google Scholar
• Szakacs Z, Dauvilliers Y, Mikhaylov V, et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(3):200.
   PubMed Web of Science ®Google Scholar
• Weaver TE, Cuellar N. A randomized trial evaluating the effectiveness of sodium oxybate therapy on quality of life in narcolepsy. Sleep. 2006;29(9):1189.
   PubMed Web of Science ®Google Scholar
• Kornum BR, Knudsen S, Ollila HM, et al. Narcolepsy. Nat Rev Dis Primers. 2017;3:16100.
   PubMed Web of Science ®Google Scholar
• Won C, Mahmoudi M, Qin L, Purvis T, Mathur A, Mohsenin V. The impact of gender on timeliness of narcolepsy diagnosis. J Clin Sleep Med. 2014;10(1):89–95.
   PubMed Web of Science ®Google Scholar
• Wilson A, Dongarwar D, Carter K, Marroquin M, Salihu HM. The association between narcolepsy during pregnancy and maternal-fetal risk factors/outcomes. Sleep Sci. 2022;15(3):297–304.
   PubMed Web of Science ®Google Scholar